Logo image of VRAX

VIRAX BIOLABS GROUP LTD (VRAX) Stock Fundamental Analysis

NASDAQ:VRAX - Nasdaq - KYG9495L1251 - Common Stock - Currency: USD

1.05  -0.04 (-3.67%)

After market: 1.08 +0.03 (+2.86%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VRAX. VRAX was compared to 105 industry peers in the Health Care Providers & Services industry. The financial health of VRAX is average, but there are quite some concerns on its profitability. VRAX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRAX had negative earnings in the past year.
In the past year VRAX has reported a negative cash flow from operations.
In the past 5 years VRAX always reported negative net income.
In the past 5 years VRAX always reported negative operating cash flow.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

VRAX's Return On Assets of -69.69% is on the low side compared to the rest of the industry. VRAX is outperformed by 90.48% of its industry peers.
Looking at the Return On Equity, with a value of -76.12%, VRAX is doing worse than 74.29% of the companies in the same industry.
Industry RankSector Rank
ROA -69.69%
ROE -76.12%
ROIC N/A
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

With a decent Gross Margin value of 39.58%, VRAX is doing good in the industry, outperforming 67.62% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VRAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRAX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, VRAX has a worse debt to assets ratio.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

VRAX has an Altman-Z score of 3.57. This indicates that VRAX is financially healthy and has little risk of bankruptcy at the moment.
VRAX has a Altman-Z score of 3.57. This is in the better half of the industry: VRAX outperforms 73.33% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that VRAX is not too dependend on debt financing.
The Debt to Equity ratio of VRAX (0.06) is better than 76.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 3.57
ROIC/WACCN/A
WACC9.02%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 11.58 indicates that VRAX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 11.58, VRAX belongs to the top of the industry, outperforming 99.05% of the companies in the same industry.
A Quick Ratio of 11.39 indicates that VRAX has no problem at all paying its short term obligations.
VRAX has a better Quick ratio (11.39) than 99.05% of its industry peers.
Industry RankSector Rank
Current Ratio 11.58
Quick Ratio 11.39
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.26% over the past year.
VRAX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.06%.
Measured over the past years, VRAX shows a quite strong growth in Revenue. The Revenue has been growing by 9.23% on average per year.
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
Revenue 1Y (TTM)7.06%
Revenue growth 3Y9.23%
Revenue growth 5YN/A
Sales Q2Q%-93.46%

3.2 Future

Based on estimates for the next years, VRAX will show a very strong growth in Earnings Per Share. The EPS will grow by 48.68% on average per year.
Based on estimates for the next years, VRAX will show a very strong growth in Revenue. The Revenue will grow by 51.03% on average per year.
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3Y41.9%
Revenue Next 5Y51.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRAX. In the last year negative earnings were reported.
VRAX is valuated quite expensively with a Price/Forward Earnings ratio of 25.74.
VRAX's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 21.38. VRAX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 25.74
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VRAX's earnings are expected to grow with 48.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.68%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (4/25/2025, 8:00:01 PM)

After market: 1.08 +0.03 (+2.86%)

1.05

-0.04 (-3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners6.72%
Inst Owner ChangeN/A
Ins Owners6.63%
Ins Owner ChangeN/A
Market Cap4.56M
AnalystsN/A
Price TargetN/A
Short Float %3.44%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 25.74
P/S 53.67
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-2.6
EYN/A
EPS(NY)0.04
Fwd EY3.89%
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.02
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.69%
ROE -76.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.58%
FCFM N/A
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 289.12%
Cap/Sales 829.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.58
Quick Ratio 11.39
Altman-Z 3.57
F-Score4
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.06%
Revenue growth 3Y9.23%
Revenue growth 5YN/A
Sales Q2Q%-93.46%
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3Y41.9%
Revenue Next 5Y51.03%
EBIT growth 1Y10.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.46%
OCF growth 3YN/A
OCF growth 5YN/A